Healthcare Industry News: Amgen
News Release - September 4, 2009
GENova names Dr. John Savin as Vice PresidentNEW YORK, NY, Sept. 4 (Healthcare Sales & Marketing Network) - (OTCBB: GVBP.OB ) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Dr. John Savin as its Vice President.
Dr. Savin will work closely with the CEO to direct GENova's growth in its business of identifying and acquiring potential drug targets and then subsequently outsourcing them to partners who can successfully usher them through clinical trials and then bring them to market.
"I am honoured to guide GENova as it positions itself as a leader in the expeditious development of innovative drugs," said Dr. Savin. "I am confident that the GENova business model will deliver new and effective therapies for patients while maximizing value for shareholders."
About John Savin, B.Sc, Ph.D., MBA
Mr. Savin builds on his 20 years experience in marketing and finance to provide strategic direction in the commercialisation and funding of innovative science on behalf of high-potential companies. His previous role was CEO of Physiomics, a systems biology company that he founded. Physiomics entered collaborations with companies like Bayer and Cyclacel, and developed a sophisticated product to optimize cancer therapeutic development. His company listed on AIM in 2004.
Prior to that, Savin worked for investment bank Gerrard Group as a pharmaceutical and biotechnology investment analyst, soon becoming a Director and a top-10-ranked City analyst. In this role, he worked with corporate finance on venture capital, many IPOs, secondary fund raising, restructuring and due diligence. Other experience includes being a Senior Consultant working at Board level with Glaxo, Zeneca, the MRC and Cabinet Office and DTi looking at issues such as the commercialization of humanized monoclonals and the strategic impact of the human genome project; and serving as International Product Manager for Pharmacia Biotech (Sweden) and Amersham International (UK). In addition to his current consulting role, Savin also writes investment research on listed biotechnology and medical devices companies. He has a B.Sc in Bioscience and Chemistry, an M.B.A. in Strategic Management, and a Ph.D in Organic Chemistry.
About GENova Biotherapeutics Inc.
GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at: www.genovabio.com.
Forward Looking Statements
This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.
Source: GENova Biotherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.